Brokerages Set Enovis Corporation (NYSE:ENOV) Target Price at $47.43

Shares of Enovis Corporation (NYSE:ENOV) have been given a consensus rating of “Buy” by the ten ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $47.4286.

A number of research analysts recently commented on the company. Needham & Company LLC upped their price objective on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Wells Fargo & Company upgraded Enovis to a “strong-buy” rating in a report on Wednesday, March 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a report on Monday, March 30th. Finally, William Blair began coverage on Enovis in a report on Friday, April 17th. They issued an “outperform” rating on the stock.

Insider Buying and Selling

In other news, insider Oliver Engert purchased 1,000 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were bought at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the purchase, the insider directly owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired 5,000 shares of company stock worth $121,983 in the last 90 days. 2.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System acquired a new position in Enovis during the first quarter worth $578,000. OP Asset Management Ltd acquired a new position in Enovis during the first quarter worth $931,000. River Road Asset Management LLC lifted its stake in Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after purchasing an additional 46,289 shares in the last quarter. Corient Private Wealth LLC lifted its stake in Enovis by 540.7% during the fourth quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock worth $1,470,000 after purchasing an additional 46,568 shares in the last quarter. Finally, Front Street Capital Management Inc. lifted its stake in Enovis by 75.8% during the fourth quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock worth $9,642,000 after purchasing an additional 156,069 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Trading Down 9.4%

ENOV opened at $23.80 on Wednesday. Enovis has a one year low of $21.00 and a one year high of $37.85. The stock has a market capitalization of $1.37 billion, a PE ratio of -1.15 and a beta of 1.47. The business’s 50 day moving average price is $23.50 and its 200 day moving average price is $26.28. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The firm had revenue of $575.76 million for the quarter, compared to analysts’ expectations of $584.30 million. During the same period in the prior year, the firm posted $0.98 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts expect that Enovis will post 3.62 EPS for the current year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.